Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

<strong>Rational<br></strong> With no available response biomarkers, matching an appropriate antidepressant to an individual can be a lengthy process. Improving understanding of processes underlying treatment responsivity in depression is crucial for facilitating work on response...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Martens, MAG, Filippini, N, Harmer, CJ, Godlewska, BR
Natura:	Journal article
Lingua:	English
Pubblicazione:	Springer Nature 2021

Documenti analoghi

Effects of escitalopram therapy on functional brain controllability in major depressive disorder
di: Fang, F, et al.
Pubblicazione: (2022)

Functional connectivity between task-positive networks and the left precuneus as a biomarker of response to lamotrigine in bipolar depression: a pilot study
di: Martens, M, et al.
Pubblicazione: (2021)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
di: Mazen K Ali, et al.
Pubblicazione: (2011-02-01)

Short-term escitalopram treatment normalizes aberrant self-referential processing in major depressive disorder
di: Komulainen, E, et al.
Pubblicazione: (2018)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
di: Mencacci C, et al.
Pubblicazione: (2013-02-01)

Effective connectivity between resting-state networks in depression
di: DeMaster, D, et al.
Pubblicazione: (2022)

Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder
di: Sophie R. Vaccarino, et al.
Pubblicazione: (2024-01-01)

Cognitive neuropsychological theory of antidepressant action: A modern-day approach to depression and its treatment
di: Godlewska, BR, et al.
Pubblicazione: (2020)

A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder
di: Ravi Babu. Komaram, et al.
Pubblicazione: (2015-06-01)

Functional Connectivity between Task-Positive Networks and the Left Precuneus as a Biomarker of Response to Lamotrigine in Bipolar Depression: A Pilot Study
di: Marieke Martens, et al.
Pubblicazione: (2021-06-01)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
di: Kishi T, et al.
Pubblicazione: (2017-01-01)

Modulatory interactions of resting-state brain functional connectivity in major depressive disorder
di: Tu Z, et al.
Pubblicazione: (2018-09-01)

Multivariate pattern analysis strategies in detection of remitted major depressive disorder using resting state functional connectivity
di: Runa Bhaumik, et al.
Pubblicazione: (2017-01-01)

Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder
di: Dominika Jarčušková, et al.
Pubblicazione: (2024-10-01)

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
di: Manal E. Alkahtani, et al.
Pubblicazione: (2021-06-01)

Escitalopram-induced akathisia in a patient with major depressive disorder: A rare case report
di: Hareem Arshad, et al.
Pubblicazione: (2022-11-01)

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
di: Kirino E
Pubblicazione: (2012-12-01)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
di: Maneeton B, et al.
Pubblicazione: (2018-08-01)

Escitalopram enhances synchrony of brain responses during emotional narratives in patients with major depressive disorder
di: Emma Komulainen, et al.
Pubblicazione: (2021-08-01)

Aberrant resting‐state functional connectivity of major depressive disorder with higher risk of suicide
di: Kazuhiro Ishikawa MD, et al.
Pubblicazione: (2022-09-01)

Decreased resting-state functional connectivity of the habenula-cerebellar in a major depressive disorder
di: Ju-Yeon Jung, et al.
Pubblicazione: (2022-09-01)

Abnormal resting-state functional connectivity of hippocampal subfields in patients with major depressive disorder
di: Zi Yu Hao, et al.
Pubblicazione: (2020-02-01)

Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis
di: Juntao Yin, et al.
Pubblicazione: (2023-11-01)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
di: Huang J, et al.
Pubblicazione: (2018-09-01)

Abnormal resting-state functional connectivity in subregions of amygdala in adults and adolescents with major depressive disorder
di: Lin Guan, et al.
Pubblicazione: (2024-07-01)

Longitudinal effects of antidepressant treatment on resting state functional connectivity in adolescents with major depressive disorder
di: K.H. Lee, et al.
Pubblicazione: (2022-06-01)

Individualized resting-state functional connectivity abnormalities unveil two major depressive disorder subtypes with contrasting abnormal patterns of abnormality
di: Keke Fang, et al.
Pubblicazione: (2025-02-01)

Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
di: Jeong JH, et al.
Pubblicazione: (2015-10-01)

Comparison of the Effect of Sertraline and Escitalopram on the Treatment of Major Depressive Disorder in Hemodialysis Patients: A Randomized Controlled Trial
di: Tahereh Sabaghian, et al.
Pubblicazione: (2024-09-01)

Review of the brain areas activated in fMRI after escitalopram antidepressant treatment inpatients with major depressive disorder
di: Mao Yi, et al.
Pubblicazione: (2021-08-01)

Treatment of alcohol dependence in patients with co-morbid major depressive disorder – predictors for the outcomes with memantine and escitalopram medication
di: Lönnqvist Jouko, et al.
Pubblicazione: (2008-10-01)

Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram: an observational study on major depressive disorder patients in southern India
di: Tatiyana Mandal, et al.
Pubblicazione: (2021-03-01)

Short-term escitalopram treatment and hippocampal volume.
di: Godlewska, B, et al.
Pubblicazione: (2014)

A Study about Escitalopram Versus Citalopram in the Treatment of Depressive Disorders
di: Jasim M. Shindi, et al.
Pubblicazione: (2015-08-01)

Alterations in electroencephalographic functional connectivity in individuals with major depressive disorder: a resting-state electroencephalogram study
di: Yingtan Wang, et al.
Pubblicazione: (2024-07-01)

Resting-state functional connectivity of the raphe nuclei in major depressive Disorder: A Multi-site study
di: Yajuan Zhang, et al.
Pubblicazione: (2023-01-01)

Efficacy and safety of repeated transcranial magnetic stimulation combined with escitalopram in the treatment of major depressive disorder: a meta-analysis
di: Zhang Liu, et al.
Pubblicazione: (2024-01-01)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
di: Pattath Narayanan Suresh Kumar, et al.
Pubblicazione: (2023-01-01)

CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
di: Rodrigo Bernini de Brito, et al.
Pubblicazione: (2020-05-01)

Baseline patterns of resting functional connectivity within posterior default-mode intranetwork associated with remission to antidepressants in major depressive disorder
di: Yanxiang Ye, et al.
Pubblicazione: (2022-01-01)